Psilocybin treatment (0.88 mg/kg) reduces the expression of several markers, including COX-2, TNF-α, IL-1β, IL-6, and IL-8, in a mouse model of brain inflammation induced by LPS. This evidence concerns the gene CXCL8 and brain inflammatory disease.